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Store-operated calcium entryAlzheimer's disease (AD) is the most widespread, age-related neurodegenerative disorder. Its two subtypes
are sporadic AD (SAD) of unknown etiology and genetically encoded familial AD (FAD). The onset of AD is
often preceded by mild cognitive impairment (MCI). Calcium dynamics were found to be dysregulated in
FAD models, but little is known about the features of calcium dynamics in SAD. To explore calcium homeo-
stasis during the early stages of SAD, we investigated store-operated calcium entry (SOCE) and inositol tri-
phosphate receptor (IP3R)-mediated calcium release into the cytoplasm in unmodiﬁed B lymphocytes from
MCI and SAD patients and compared them with non-demented subjects (NDS). Calcium levels in the endo-
plasmic reticulum and both the rising and falling SOCE slopes were very similar in all three groups. However,
we found that SAD and MCI cells were more prone to IP3R activation than NDS cells, and increases in calcium
levels in the cytoplasm were almost twice as frequent in SAD cells than in NDS cells. MCI cells and SAD cells
exhibited an enhanced magnitude of calcium inﬂux during SOCE. MCI cells but not SAD cells were character-
ized by higher basal cellular calcium levels than NDS cells. In summary, perturbed calcium homeostasis was
observed in peripheral cells from MCI and SAD patients. Thus, lymphocytes obtained from MCI subjects may
be promising in the early diagnosis of individuals who will eventually develop SAD. However, no conclusions
are made regarding SAD due to the limited number patients. This article is part of a Special Issue entitled:
12th European Symposium on Calcium.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Alzheimer's disease (AD) is the most common age-related, neuro-
degenerative disorder, characterized by progressive neuronal loss
that leads to cognitive, memory, and behavioral impairments. AD
has been diagnosed through patient history of cognitive decline
and postmortem ﬁndings of extracellular plaques of amyloid β
(Aβ) protein aggregates and intracellular neuroﬁbrillary tangles (NFTs)
composed of hyperphosphorylated tau protein. At least two types of
AD can be distinguished: sporadic Alzheimer's disease (SAD), which ac-
counts for most cases, and familial Alzheimer's disease (FAD), which af-
fects up to 5% of all AD patients and is caused by mutations in amyloid
precursor protein (APP) or presenilin proteins 1 or 2 (PS1, PS2) [1].
These proteins participate in Aβ production, in which presenilins are
part of a larger protein complex (i.e., γ-secretase) that is responsibleopean Symposium on Calcium.
eration, International Institute
09 Warsaw, Poland. Tel.: +48
.
-NC-ND license.for theﬁnal cleavage of APP to generate Aβ. Mostmutations in these pro-
teins favor the production of a toxic, amyloidogenic form of Aβ, Aβ42 [2].
The molecular mechanism of FAD pathology appears to be well un-
derstood and enabled the construction ofmany animalmodels. Howev-
er, the etiology of SAD is still unknown. Until recently, the deposition of
protein aggregates was widely accepted to be a proximal cause of path-
ogenesis in both FAD and SAD [3]. However, some differences between
these two types of AD have lately been identiﬁed (reviewed in [4,5]).
The appearance of plaques has been suggested to be a result of earlier
pathological events and is not the only factor responsible for the pathol-
ogy of the disease (reviewed in [6]). Currently, very few experimental
studies have directly compared FAD and SAD or the etiology of SAD it-
self. SAD is particularly difﬁcult to study because of a lack of appropriate
animal models of the disease. The only material available for study is
obtained from patients. Since SAD is believed to be a systemic disorder,
changes might occur not only in neurons but also in peripheral cells,
such as ﬁbroblasts or blood cells [7–9].
Altered calcium homeostasis has recently emerged as one of the
early events responsible for AD. Calcium can be linked both to FAD
pathology, mostly by interactions between mutated presenilins and
several molecules involved in ER calcium homeostasis or by loss of
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as to SAD pathology, directly by altering Aβ generation and tau pro-
tein hyperphosphorylation or indirectly, mostly by calcium changes
connected with aging (reviewed in [13,14]). The most convincing
evidence showing the involvement of calcium aberration in AD is
the fact, that one of the two drugs which are effective in AD treatment
is memantine—a partial antagonist of N-methyl-D-aspartate receptor
(NMDAR, nonselective cation channel).
The correlation between increased cytosolic calcium level, increased
calcium ﬂuxes and higher production of Aβ iswell established [15,16]. It
appears that almost all ER calcium related proteins are connected with
Aβ production. The inhibition of SERCA pump leads to the inhibition of
Aβ generation, whereas overexpression of SERCA increases Aβ accumu-
lation [17]. Additionally inhibition of SOCE causes increased Aβ42 pro-
duction [18]. Furthermore, knockdown of the IP3R reduces [19], while
expression of RyR increases [20] Aβ production. In vivo imaging of
neurites and spines of APP overexpressing mice revealed, that spines
which are located in proximity to Aβ plaques showed increased basal
calcium levels. The consequences include abnormal spines morphology
and disrupted calcium compartmentalization [21].
Many recent studies have shown a strong correlation between PS1
and PS2 mutations in FAD models and calcium dyshomeostasis. Such
changes in calcium handling are mostly associated with calcium ion
ﬂux from the endoplasmic reticulum (ER) via two types of calcium
channels: inositol triphosphate receptors (IP3Rs) and ryanodine re-
ceptors (RyRs).
IP3 receptor activity was found to be signiﬁcantly increased in
Xenopus laevis oocytes that overexpress mutant PS1 and PS2 [22,23],
mouse PS1 knock-in cortical neurons [24], and lymphoblasts derived
from FAD patients [25]. A recent study showed that the expression of the
FADmutant PS constitutively activates cyclic adenosine monophosphate
(cAMP) response element binding protein (CREB) and inﬂuences CREB-
responsive gene expression in both cultured neuronal cells and mouse
models of AD [26]. This was one of the ﬁrst studies that showed a causal
link between calcium dyshomeostasis and alterations in signaling path-
ways that possibly lead to neuronal dysfunction.
Increased RyR expression and exaggerated RyR calcium signalingwas
found in several ADmousemodels that boremutated PS1 [27–30]. An al-
tered RyR expression pattern was found in human brain AD specimens
and correlated with tau and amyloid pathology [31]. Presenilin-linked
disruptions in RyR signaling and subsequent calcium-induced calcium
release via NMDAR-mediated calcium inﬂuxwas shown to alter synaptic
function, providing additional evidence of a strong link between calcium
handling and the functioning of neurons in FAD [32].
Store-operated calcium entry (SOCE) is a mechanism that enables
the replenishment of depleted ER calcium stores. SOCE was shown to
be downregulated in mouse PS1 knock-in ﬁbroblasts [33], human neu-
roblastoma that overexpressed PS1 [34], cortical neurons fromdifferent
FAD models [35], human microglia [36], and lymphoblasts obtained
from FAD patients [37]. Mutations in presenilins, therefore, may disrupt
various aspects of calcium homeostasis and contribute to neuronal
failure.
Interestingly, some changes in calcium homeostasis were also ob-
served in peripheral cells obtained from SAD patients [38–41]. A more
comprehensive dataset that reveals aberrant calcium signaling in periph-
eral cells derived from SAD patientsmay help better understand themo-
lecular basis of the disease and relationship between FAD and SAD.
Mild cognitive impairment (MCI) is deﬁned as the presence of
cognitive impairments that are more severe than those expected at
a certain age but not signiﬁcant enough to interfere with everyday ac-
tivities [42]. Mild cognitive impairment does not fulﬁll the criteria of
AD or any other dementia. It is often observed in individuals who de-
velop AD later in life and therefore may be considered a risk factor for
AD [42–44]. Little is known about calcium dysregulation in MCI, but
RyR expression patterns were shown to be different between MCI
and AD groups [45].The present study investigated the changes in calcium handling
observed in unmodiﬁed lymphocytes derived from SAD patients and
MCI subjects. We focused on the two major cytoplasmic calcium entry
mechanisms: SOCE and IP3R-dependent ﬂux. To our best knowledge,
there was no study concerning IP3R mediated signals in unmodiﬁed
lymphocytes B from SAD patients, despite very promising results
obtained for FAD lymphocytes bearing presenilin mutations. Also, no
broad spectrum analysis including kinetics of the SOCE reaction was
made in cells obtained from SAD patients. The use of fresh lymphocytes
B is critical, because most of the experiments to date were carried on
immortalized lymphocytes B from AD patients and it is known, that
the process of immortalization interferes with cell metabolism and cal-
cium handling [46,47]. Our results showed that cells derived from the
MCI group were characterized by increased SOCE calcium inﬂux and
basal calcium levels. The cells derived from SAD patients exhibited a
higher response to IP3R stimulation. These data conﬁrm some of the
previous observations in FAD cells and provide new information about
early calcium aberrations that likely lead to SAD.
2. Materials and methods
2.1. Subjects
Samples of peripheral venous blood were obtained from 16 SAD
patients aged 57–86 years (mean, 75±8 years), 28 MCI subjects aged
58–84 years (mean, 69±9 years), and 22 non-demented subjects
(NDS) aged 60–84 years (mean, 73±7 years). All of the subjects were
considered for the IP3R calcium signaling measurements. Due to the
failure of hardware during SOCE measurements the samples from
three SAD patients and one MCI subject could not be collected.
The subjects' demographic and clinical characteristics are reported
in Table 1. The SAD patients and MCI subjects were recruited from the
Alzheimer's Disease Department at the Ministry of Internal Affairs
Hospital, Warsaw, Poland. The non-demented subjects were recruited
from the Cardiovascular Disease Clinic at Banacha's Hospital, Warsaw,
Poland. The SADandMCI subjects underwent detailedmedical, neuropsy-
chological, neurological, and psychiatric examinations. Close informants
were interviewed, and laboratory testing and computed tomography or
magnetic resonance imaging of the brainwere performed. The clinical di-
agnosis of probable ADwasmade according to the criteria of the National
Institute of Neurological and Communicative Disorders and Stroke and
Alzheimer's Disease and Related Disorders Association [48]. Mayo Clinic
criteria were used to diagnose MCI [49]. Two MCI and two AD patients
suffered from infections or immune diseases. The exclusion of the results
obtained for these subjects doesn't change the statistical signiﬁcance of
the results. The NDS group consisted of subjects with no apparent neuro-
logical disease or psychiatric syndrome, no complaints ofmemory impair-
ment, and a Mini-Mental State Examination score≥27. The exclusion
criteria for NDS included autoimmune diseases, neoplasms, and acute or
chronic inﬂammation. BecauseNDSwere recruited from theCardiovascu-
lar Disease Clinic, most of them suffered from cardiovascular diseases
(CVD). CVD is one of the many risk factors for AD [50] and aging is one
of the risk factors for both AD and CVD [50]. Therefore, aged cardiovascu-
lar patients who showed no signs of dementia can be considered as AD
“escapees”. All of the participants were informed of the purpose of the
study and gave their informedwritten consent. The projectwas approved
by the Bioethical Committee for Studies on Human Subjects at Central
Clinical Hospital MSWiA in Warsaw (approval no. 08/2011).
2.2. Preparation of cells
Blood samples were collected between 8:00 and 9:00 AM. Peripheral
blood mononuclear cells were isolated from 6 ml of venous blood col-
lected in lithium heparin-treated tubes (BD Vacutainer, BD Biosciences)
by standard density gradient centrifugation (LSM 1077 Lymphocyte,
PAA). Brieﬂy, blood was mixed in a 1:1 ratio with phosphate-buffered
Table 1
Demographic and clinical information for Alzheimer's disease patients (SAD group),
mild cognitive impairment subjects (MCI group), and non-demented subjects (NDS
subjects).
SAD MCI NDS
Age
(years)/
sex
MMSE CDR GDS Age
(years)/
sex
MMSE CDR GDS Age
(years)/
sex
MMSE
57/M 19 1/2 5 54/F 30 0/0.5 3 57/M 29
62/F 24 1 3/4 56/F 25 0.5 2/3 60/M 30
69/M 20 1/2 4 57/M 29 0.5 3 62/M 30
70/F 26 0.5/1 4 58/F 30 0.5 3 64/F 30
74/Fa 23 1/2 4 58/M 28 0.5/1 2 65/F 30
74/M 20 1/2 4 58/F 25 0 2/3 65/M 29
75/F 25 1 4 60/M 25 0.5 3 66/F 30
76/F 20 1 3/4 60/M 28 0 2/3 67/F 28
77/Fa 17 1 3/4 62/M 28 0.5 3 67/F 29
78/F 22 1 3/4 63/M 25 0.5 3 70/M 30
79/M 17 2 4/5 64/F 28 0/0.5 3 72/F 30
80/Fa 26 0.5 3 66/M 27 0/0.5 3 73/F 27
80/M 23 1 3/4 68/M 27 0.5 3 74/F 30
83/F 26 1 3 70/F 28 0.5 3 74/F 29
84/F 23 1 3/4 70/F 26 0.5 3 75/M 29
86/M 22 1/2 4/5 70/M 25 0.5 3 77/M 30
70/F 30 0/0.5 3 78/M 30
72/M 30 0/0.5 3 78/F 29
72/M 25 0.5 3 80/F 29
72/M 30 0.5 3 81/F 30
73/M 27 0.5 3 81/F 27
75/Fa 29 0.5 2 84/M 29
81/M 28 0 3
81/M 28 0 3
81/F 26 0.5 3
82/M 29 0.5 2
83/M 27 0.5 3
84/F 27 0.5 3
Average Mode Average Mode Average
75±8 22±3 1 3.5 69±9 28±2 0.5 3 73±7 29±1
F, female; M, male; MMSE, Mini-Mental State Examination; CDR—Clinical Dementia
Rating; GDS—Global Deterioration Scale.
a Subjects absent from the SOCE analysis.
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containedmononuclear cells waswashed twicewith PBS. Human B lym-
phocytes were isolated with the Dynabeads Untouched Human B Cells
kit (Invitrogen, Life Technologies) according to themanufacturer's proto-
col. The cells were cultured overnight in RPMI 1640 medium with 1%
HEPES and 1% penicillin–streptomycin supplemented with 10% fetal
bovine serum and 2% L-glutamine (all from Sigma-Aldrich). The next
day, the cells were attached to poly-L-lysine-coated Lab-Tek Chambered
Coverglass eight-well slides (Nunc) for 2 h.
2.3. Calcium measurements
Fura-2 digital ﬂuorescence microscopy was used to determine
changes in intracellular Ca2+ levels [51]. Brieﬂy, before the experiment,
the culture medium was replaced for 30 min by 2 μM Fura-2 AM
(Molecular Probes, Life Technologies) in a solution that contained
145 mM NaCl, 5 mM KCl, 0.75 mM Na2HPO4, 10 mM glucose, 10 mM
HEPES (pH 7.4), and 1 mM MgCl2 (standard medium) supplemented
with 2 mM CaCl2 (high-calcium medium) at 37 °C. The cells were then
washed by 15 min incubation with standard medium supplemented
with 0.5 mM ethylene glycol tetraacetic acid—EGTA (low-calciummedi-
um) for SOCE or 2 mM CaCl2 for IP3R calcium signaling measurements.
The Lab-Teks were mounted on an Olympus Scan^R/Cell^R imaging
system equipped with an IX81 inverted microscope, MT20 illuminator
(Xenon lamp, high-speed ﬁlter wheel with 340 and 380 nm ﬁlters),
and cage incubator (Life Imaging Services, Basel, Switzerland) set at
37 °C. Images were taken with a 40×/0.95 objective and Hamamatsu
C9100-02 EM-CCD camera. Data acquisition and analysis were
conducted using Olympus Cell^R software. SOCE measurements wereinitiated in the low-calcium medium. After 3 min, 1 μM thapsigargin
(TG) was added (Sigma-Aldrich). After 5 min, calcium was added to
yield a ﬁnal concentration of 2 mM. Measurements of IP3R calcium re-
sponses began in a calcium medium that was replaced 7.5 min later
by the same one that contained 5 μg/ml Gt F(ab')2 Anti-Human IgM an-
tibody (Invitrogen). The experiment was carried out in parallel for sub-
jects from various groups and no differences in highest and lowest
Fura-2 ratios were detected. In human lymphocytes calcium measure-
ments were performed by others to analyze dialysis patients and with
chronic renal failure [52].
2.4. Data processing
Fura-2 signals were analyzed using a custom computer program
(details and software available upon request: j.dzbek@gmail.com).
This automated approach allowed for the elimination of personal bias
in the data evaluation and made the extraction of a broad range of pa-
rameters feasible from a large dataset of available signals, in which a
total of 1500 single cell responses were recorded. Using this custom
software, the following parameters were quantiﬁed:
– SOCE: Calcium signal baseline value (basal), area-under-the-curve
(AUC) after the addition of TG to the low-calcium medium (AUC
ER, representing the releasable calcium pool in the ER), AUC in
the high-calcium medium (AUC SOCE, showing Ca2+ inﬂux in
SOCE), calcium peak height (peak ΔCa2+), maximum rise and
maximum fall rates of SOCE peak (↑Ca2+ slope and ↓Ca2+ slope,
respectively), and calcium level at the end of the measurement
(ﬁnal Ca2+).
– IP3R signals: Presence of spontaneous peaks before the addition of
IgM antibody, presence of response of the cell to anti-IgM stimulation,
presence of an additional calcium increase after anti-IgM stimulation.
The acquired calcium time-courses were initially down-sampled
and de-noised using a Wiener ﬁlter. Several custom-developed heu-
ristic algorithms were then applied. The ﬁrst step involved ﬁnding
the local maxima of the signal and its derivative and other locally es-
timated values. In the second step, the results from the ﬁrst step were
properly aggregated to acquire the value of the speciﬁc signal param-
eter. The aggregation step was controlled by parameters that were
manually adjusted on a subset of representative signals. Their values
were selected to ensure the best algorithm speciﬁcity and sensitivity.
Finally, all of the calculated signal parameter values were graphically
inspected to avoid obvious errors that may have arisen from insufﬁ-
cient signal quality or algorithm problems.
2.5. Statistical analysis
The statistical analysis was performed using PRISM software ver-
sion 5.02 (GraphPad Software, San Diego, CA) and one-way analysis
of variance (ANOVA) followed by Tukey's multiple test for comparing
three groups. A normal distribution of the data from all of the exper-
iments was indicated using the D'Agostino–Pearson normality test.
Differences were considered signiﬁcant at a level of pb0.05. Each
symbol represents the mean value of four independent experiments.
The number of cells measured in four independent experiments ranged
from 10 to 223 each (average, 70±46). Horizontal lines in the ﬁgures
represent mean values within a group. The bars indicate the standard
deviation (*pb0.05, **pb0.01).
3. Results
3.1. B lymphocytes exhibit heterogeneous IP3R-mediated calcium response
B lymphocytes were puriﬁed from blood samples obtained from SAD
patients, MCI subjects, and non-demented subjects (NDS; Table 1). For
each type of cell, two calcium entry routes into the cytoplasm were
Fig. 1. Representative IP3R-mediated calcium signaling induced by immunoglobulin M an-
tibody (anti-IgM). Two types of responses were triggered by anti-IgM stimulation. The
black line indicates a single calcium peak followed by a decrease in calcium concentration.
In some cases, the IP3R signals were followed by additional calcium inﬂux, indicated by the
gray line. IP3R-mediated calcium signaling in B lymphocytes was elicited by binding the B
cell receptor (BCR)with a high concentration (5 μg/ml)of anti-IgM in the high-calciumme-
dium. The dotted line indicates a representative cell responsewith spontaneous calciumos-
cillations observed in the high-calcium medium before anti-IgM stimulation.
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the extracellular space. The collected data were analyzed, and the fea-
tures and quantitative parameters of the responses were compared be-
tween each of the three groups (Table 2). When IP3 receptors were
activated with anti-IgM antibodies (anti-IgM) via the B cell receptor
(BCR) pathway, two types of calcium responses in humanB lymphocytes
were observed. In 48% of responding cells, a single, transient calcium
peak was recorded (Fig. 1, black line). In remaining responding cells,
anti-IgM stimulation triggered a calcium peak that was followed by a
sustained increase in calcium levels (Fig. 1, gray line). 54% of cells
exhibited spontaneous calcium oscillations in a high-calcium medium
(Fig. 1, dotted line). Spontaneous calcium oscillations were dependent
on extracellular calcium, as in a calcium free medium none or very
few oscillations were detected (data not shown).
3.1.1. Fraction of cells with spontaneous oscillations is decreased in SAD
cells
We ﬁrst compared the number of cells that exhibited spontaneous
calcium oscillations. The relative number of oscillating cells was sig-
niﬁcantly lower in SAD cells and slightly lower in MCI cells than in
NDS cells (Fig. 2A).
3.1.2. SAD lymphocytes are more sensitive to anti-IgM-induced
activation
We next compared the responses of B lymphocytes to anti-IgM-
induced activation (i.e., whether IP3Rs are more prone to activation
in SAD or MCI cells than in NDS cells). As shown in Fig. 2B, 17% of
NDS cells responded to the stimulation, whereas the percentages
were 23% and 27% in cells from MCI subjects and SAD patients, re-
spectively. All of the response types were considered. The difference
between SAD and NDS was statistically signiﬁcant.
3.1.3. Fraction of cells that respond with cytoplasmic calcium inﬂux after
anti-IgM-induced activation is doubled in SAD cells
As shown in Fig. 1, the activation of IP3R in some cells was followed
by sustained calcium inﬂux. The relative number of these cells in the
SAD group was increased by approximately 16% compared with 8.5%
in NDS cells and 11% in MCI cells (Fig. 2C). The difference between
SAD and NDS was statistically signiﬁcant. A summary of these data is
shown in Table 2.
3.2. Quantitative parameters of SOCE in B lymphocytes
B lymphocytes were treated with thapsigargin (TG), the sarco/
endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitor, in a
low-calciummedium to empty ER calcium stores. After store depletion,
the medium was enriched with calcium to induce SOCE. SeveralTable 2
Summary of parameters of calcium dynamics in lymphocytes from non-demented sub-
jects (NDS), sporadic Alzheimer's disease patients (SAD), and subjects with mild cogni-
tive impairment (MCI).
Parameter Comparison
between
groups
Fold
change
Figure
number
Fraction of cells with spontaneously
occurring oscillations (%)
NDS>SAD 1.4* 2A
Fraction of cells with activation of IP3
receptors (%)
SAD>NDS 1.6* 2B
Fraction of cells with calcium inﬂux from
the medium after IP3R activation (%)
SAD>NDS 1.9* 2C
Basal calcium level in cytoplasm (Fura-2 ratio) MCI>NDS 1.1** 4
ER calcium efﬂux (AUC ER) SAD=MCI=NDS – 5
Calcium inﬂux during store-operated calcium
entry (AUC SOCE)
MCI>NDS 1.3* 6A
Calcium peak height (Fura-2 ratio) MCI>NDS
MCI>SAD
1.2*
1.3*
6B
Asterisks (*, **) indicate statistical signiﬁcance.parameters of calcium dynamics were derived from the recorded
signals. Basal calcium levels were estimated before the addition of
TG. The AUC in the low-calcium medium in the presence of TG
(AUC ER) reﬂected the amount of calcium released from the ER,
whereas the AUC in the high-calcium medium reﬂected the extentFig. 2. Percentage of B lymphocytes cells with various increases in calcium. (A) Percentage
of lymphocytes with spontaneous oscillations. Spontaneous oscillations were observed in
the high-calciummedium for 2 min before the addition of anti-IgM (*pb0.05). (B) Percent-
age of the cells shown in Fig. 1 that responded to IgMantibody. Lymphocyteswere incubat-
ed in a high-calcium medium. After 7.5 min, anti-IgM was added at a ﬁnal concentration
5 μg/ml (*pb0.05). (C) Percentage of cells in which anti-IgM triggered inﬂux of calcium
frommedium. In the majority of the cases, IP3R stimulation was followed by calcium inﬂux
from the high-calcium medium (*pb0.05).
Fig. 4. Basal calcium level in human B lymphocytes. Lymphocytes were incubated in a
low-calcium medium to avoid the occurrence of spontaneous peaks. Relative basal cal-
cium levels were measured during the ﬁrst 2 min of the experiment before the addi-
tion of thapsigargin (TG) (**pb0.01).
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culated in the high-calcium medium are shown in Fig. 3, including
peak amplitude (peak ΔCa2+), the rising slope of the calcium peak
(↑Ca2+ slope), and the falling slope of the peak (↓Ca2+ slope). All
of these parameters were compared between the three groups
(Figs. 4–6).
3.2.1. Basal calcium levels are increased in lymphocytes from MCI
subjects
We compared basal calcium levels in resting cells. In MCI cells, the
level was signiﬁcantly higher than in NDS cells (Fig. 4). The exclusion
of the outliers in the MCI group did not change the statistical signiﬁ-
cance of the results (Table 2).
3.2.2. Releasable calcium pool in the ER is unchanged between groups
To empty ER calcium stores, TG was added to the low-calciumme-
dium. The amount of calcium stored in the ER was estimated by mea-
suring the AUC (AUC ER). No differences were found in the releasable
calcium pool from the ER in SAD, MCI, and NDS cells (Fig. 5, Table 2).
3.2.3. SOCE is enhanced in MCI cells
We next compared the dynamics parameters of SOCE calcium in-
ﬂux evoked by calcium enrichment of the medium. Two of the ana-
lyzed parameters differentiated the cells from MCI patients and NDS
individuals, speciﬁcally the overall amount of calcium that entered the
cell (AUC SOCE) and calcium peak amplitude (Fig. 6A, B). Additionally,
the calcium peak amplitude was signiﬁcantly lower in the SAD group
than in the MCI group. The other three parameters did not signiﬁcantly
discriminate the cells from the analyzed groups (i.e., rise and fall rates of
the SOCE peak [↑Ca2+ slope and ↓Ca2+ slope, respectively]; Fig. 6C, D;
calcium level at the end of the measurement [ﬁnal Ca2+]; data not
shown).
4. Discussion
Alzheimer's disease is one of the most extensively studied neuro-
degenerative disorders. Most research has focused on animal models
or post mortem human brain specimens. However, post mortem anal-
ysis provides information about the latest stages of the disease, and
animal models enable the investigation of FAD but not necessarily
SAD. The majority of animal models were generated based on the am-
yloid and tau hypothesis, which insufﬁciently explains the induction
of sporadic AD pathology (reviewed in [53]). Most of the drugs devel-
oped based on the amyloid hypothesis (i.e., drugs that seek to reduce
Aβ amyloid production, prevent Aβ aggregation, clear amyloid deposits,
or target tau phosphorylation and assembly) have failed in late clinical
trials (reviewed in [54]). Therefore, expanding our view of SAD and
searching for other possible causes of the disease that are responsibleFig. 3. Single-cell calcium traces during store-operated calcium entry. Cells were incubated
in a low-calcium medium. SOCE was evoked by the addition of 1 μM thapsigargin (TG)
followed by the addition of a high-calcium medium. Each of the analyzed parameters is
indicated.for its onset are necessary. The establishment of early diagnosis and re-
liable biomarkers is critical, and the use of peripheral cells may be a so-
lution, in addition to brain imaging and cerebrospinal ﬂuid biomarker
analyses.
Alzheimer's disease is considered a brain disease, but the periphery
also appears to be involved. Indeed, AD shows typical peripheral effects,
with changes in ﬁbroblasts and blood cells, including enhanced oxida-
tive stress, impaired cellular calcium dynamics, and mitochondrial dys-
function [55,7,56–58]. All of these pathological processes observed in
peripheral cells long precede plaque formation in neurons, making
themperfect tools for early diagnosis [59,24]. A strong correlation exists
between mitochondrial dysfunction, which leads to oxidative damage,
and changes in cellular calcium homeostasis. Interference with metab-
olism increases cytosolic free calcium and alters intracellular calcium
dynamics [60]. Thus, these processes might be considered to be linked
in a chain of events.
In the search for possible biomarkers, a very helpful approach is to
use peripheral cells obtained fromMCI subjects. The rate of progression
from MCI to AD is estimated to be almost seven-fold higher than the
progression to AD in individuals without cognitive impairment [43].
Unfortunately, very few studies have compared changes in peripheral
cells from AD andMCI subjects. Increased DNA damage, particularly at-
tributable to oxidized purines and pyrimidines, was found in peripheral
cells from AD and MCI subjects [61]. A reduction of the complex IV ac-
tivity of platelets was reported in AD andMCI [62]. Enhanced apoptotic
death, elevated SOD mRNA, and an elevated Bax/Bcl2 ratio were found
in peripheral blood mononuclear cells from MCI and AD subjects [63].
Plasma antioxidant levels were also shown to be decreased in both AD
and MCI [64]. Mitochondrial dysfunction in lymphocytes from AD and
MCI patients without any Aβ or tau pathology points to the relevance
of these changes in the cascade of events that leads to brain failure.
An exaggerated IP3R response in AD samples was reported in the
early 1990s, and diagnostic criteria for ﬁbroblasts from both FAD and
SAD patients were proposed [40]. More recently, a possible mechanism
was discovered. Presenilins 1 and 2 were shown to interact with IP3Rs,
andmutations in PS enhanced the gating of IP3R Ca2+ channels through
a gain-of-function effect that was independent of γ-secretase activity.
These data were obtained in FAD lymphoblasts and murine neuronsFig. 5. Releasable calcium pool from the endoplasmic reticulum in AD,MCI, and NDS cells.
The AUC was calculated for cells treated with 1 μM thapsigargin (TG) in a low-calcium
medium for 5 min. No changes were observed between the three groups of cells.
Fig. 6. SOCE increased in B lymphocytes obtained from MCI subjects. (A, B) AUC–SOCE and maximum calcium level during SOCE (peak ΔCa2+) were calculated during 8 min of
calcium inﬂux in a high-calcium medium after blocking the SERCA pump with 1 μM thapsigargin (TG) (*pb0.05). (C, D) Rising and falling slopes of SOCE reaction, respectively.
The slope was calculated as a change in calcium concentration over time.
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were observed in SAD cells, in which presenilin was not mutated.
The present study found an exaggerated IP3R response in unmodiﬁed
lymphocytes from SAD patients. The percentage of cells in which IgM
triggered a calcium response followed by additional calcium inﬂux was
also higher in SAD cells. Such a prolonged and enhanced calcium
presence in cells may inﬂuence basic cell pathways and contribute
to oxidative changes. For example, dysregulated phosphorylation
of Ca2+/calmodulin-dependent protein kinase II-α was found in
the hippocampus of subjects with MCI and SAD [65]. An interesting
observationwas that the percentage of cells with spontaneous activation
was smaller in SAD and MCI cells than in cells from non-demented sub-
jects. There is an inverse correlation between the number of spontaneous
peaks and the magnitude of the response to anti-IgM stimulation, but
there is no inverse correlation between the occurrence of the oscillations
and the presence of the anti-IgM response. Thismay indicate that the be-
havior of SAD andMCI cells changes because of an ongoing inﬂammatory
process. Thiswould support involvement of inﬂammation in SADpathol-
ogy (reviewed in [66]).
Notably, we observed a gradation of changes in the case of IP3R
mediated responses in all three groups, with the most pronounced
changes seen in SAD and fewer in MCI. This may support the hypoth-
esis that MCI is an intermediary step between non-dementia status
and SAD. In the case of SOCE and basal calcium level, NDS and SAD
group shared similar results, with outstanding results obtained for
the MCI group. As discussed later, the SAD data may indicate that
after the initial pathological increase in SOCE and basal calcium levels
observed during the MCI stage, the compensating mechanism occurs
during later stages of the disease. However, SAD cells were initially
obtained from 16 patients, but 3 samples could not be analyzed because
of hardware problems. This brought down the number of patients to 13,
but two of themhad infections, which could affect calciumhomeostasis.
Therefore, the ﬁnal number of samples is low to make conclusive re-
marks about physiological signiﬁcance of these observations. SOCE has
been reported to be decreased in FAD cells, but some reports have
found either no changes or an increase in SOCE (reviewed in [11]).
The present study found no changes in the magnitude and kinetics of
SOCE in SAD cells, but MCI cells were characterized by enhanced
SOCE. We hypothesize that exaggerated SOCE occurs at the beginningof the disease and then is compensated (in the case of early symptom-
atic stages of SAD) or downregulated (in the case of advanced SAD) by
some yet unknownmechanism. The releasable pool of calcium from the
ER was unchanged in all three groups, consolidating the notion that the
“store overload hypothesis” does not explain the increase in calcium
responses from the ER observed in SAD but rather exaggerated IP3R
single-channel activity [25] or RyR overexpression [30]. We showed
that basal calcium levels were increased in MCI cells. Such increases
were not observed in SAD cells, consistentwith the data reported earlier
inﬁbroblasts fromSADpatients and control subjects [67]. Enhanced cal-
cium signalingmay therefore be a triggeringmechanism in SAD pathol-
ogy that occurs at the very early stages of the disease. Enhanced SOCE
and increased basal calcium levels inMCI subjects can signiﬁcantly inter-
fere with cellular metabolism and consequently impair many signaling
pathways, activate calcium-dependent enzymes, and trigger pathologi-
cal processes, such as oxidative stress and apoptosis.
Some reports show that pathological changes observed inAD are not
restricted to neurons, but can be observed in ﬁbroblasts and blood cells.
Such peripheral cells have been therefore considered as cellularmateri-
al for drug screening, and as a potential easily available diagnostic ma-
terial. Some changes are observed in subjects with MCI that may be
considered an AD risk factor. To follow the clinical outcome of the MCI
subjects analyzed in these studies would be very interesting to see
whether the patients with the highest calcium changes develop AD. If
so, then lymphocytes obtained from MCI subjects may be a promising
material for early diagnosis in groups at-risk for SAD.
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